92 related articles for article (PubMed ID: 21204722)
21. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
22. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
Jahangiri S; Friedberg J; Barr P
Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
[TBL] [Abstract][Full Text] [Related]
23. Anti-neoplastic effects of fucoxanthin and its deacetylated product, fucoxanthinol, on Burkitt's and Hodgkin's lymphoma cells.
Tafuku S; Ishikawa C; Yasumoto T; Mori N
Oncol Rep; 2012 Oct; 28(4):1512-8. PubMed ID: 22859062
[TBL] [Abstract][Full Text] [Related]
24. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
Bargou RC; Emmerich F; Krappmann D; Bommert K; Mapara MY; Arnold W; Royer HD; Grinstein E; Greiner A; Scheidereit C; Dörken B
J Clin Invest; 1997 Dec; 100(12):2961-9. PubMed ID: 9399941
[TBL] [Abstract][Full Text] [Related]
25. Current treatment strategies in Hodgkin lymphomas.
Copeland A; Younes A
Curr Opin Oncol; 2012 Sep; 24(5):466-74. PubMed ID: 22871744
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials.
Bar Ad V; Paltiel O; Glatstein E
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1472-9. PubMed ID: 19028275
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
29. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
30. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
31. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.
Aldinucci D; Gloghini A; Pinto A; De Filippi R; Carbone A
J Pathol; 2010 Jul; 221(3):248-63. PubMed ID: 20527019
[TBL] [Abstract][Full Text] [Related]
32. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
33. Emerging drugs for Hodgkin's lymphoma.
Böll B; Borchmann P; Diehl V
Expert Opin Emerg Drugs; 2010 Dec; 15(4):585-95. PubMed ID: 20629601
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.
Baues C; Semrau R; Gaipl US; Bröckelmann PJ; Rosenbrock J; Engert A; Marnitz S
Strahlenther Onkol; 2017 Feb; 193(2):95-99. PubMed ID: 27704149
[TBL] [Abstract][Full Text] [Related]
35. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
36. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
37. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.
Carbone A; Spina M; Gloghini A; Tirelli U
Am J Hematol; 2011 Feb; 86(2):170-9. PubMed ID: 21264899
[TBL] [Abstract][Full Text] [Related]
38. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
39. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
40. [The molecular pathogenesis of classical Hodgkin lymphoma].
Mathas S; Dörken B; Janz M
Dtsch Med Wochenschr; 2009 Sep; 134(39):1944-8. PubMed ID: 19760557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
